15 Surprising Statistics About Psychedelic Therapy’s Mental Health Impact
Last reviewed and updated: July 5, 2026
Key Takeaways
| Market size | The U.S. ketamine therapy market generates over $400 million per quarter; Spravato (esketamine) is on track to become a $3.5 billion drug by 2028. |
| Clinical trial volume | Over 400 psychedelic clinical trials are currently registered on ClinicalTrials.gov — representing a 10x increase from a decade ago. |
| Psilocybin population | A 2024 study estimated that 5 million Americans could benefit from psilocybin therapy for treatment-resistant depression alone — representing a fraction of the overall addressable population. |
| Practitioner shortage | Oregon has 300+ licensed psilocybin facilitators; industry projections suggest tens of thousands would be needed if psilocybin receives FDA approval. |
| MDMA efficacy | MDMA-assisted therapy produced 67-71% PTSD response rates in Phase 3 trials — among the highest ever recorded for a psychiatric treatment — despite the FDA’s 2024 rejection on methodology grounds. |
If you’re reading this, there’s a good chance you’re well aware of the potential of psychedelics to treat a wide range of mental health issues. But the vast majority of society still thinks of these drugs as, well…drugs…and nothing more. But the truth is there have been numerous clinical trials and studies by vetted institutions (i.e. actual scientists in white lab coats). And these studies show the potential that psychedelics hold. This isn’t just the stuff for Phish shows. Psilocybin, ketamine, MDMA, ayahuasca, ibogaine, DMT and a few others have the potential the change the mental health treatment landscape forever. (This is just one reason why the FDA approved ketamine to treat depression. And why it looks like the FDA may approve MDMA to treat PTSD in late 2024.)
So the next time you’re having a conversation with someone who may not be a believer, pull out a few of these statistics to help them understand.
RELATED: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
15 Super Surprising Statistics About Psychedelics Potential for Mental Health Treatment
1. Psilocybin for Depression:
In a study, 71% of participants with major depression showed more than 50% reduction in symptoms four weeks after two psilocybin sessions (Johns Hopkins Medicine).
RELATED: Study: Psilocybin Better Than SSRIs in Treating Depression
2. Ketamine for Depression:
A study found that ketamine rapidly reduced suicidal thoughts in 55% of patients with treatment-resistant depression (American Journal of Psychiatry).
3. Ibogaine for Opioid Addiction:
Research indicated a 50% reduction in opioid withdrawal symptoms after a single dose of ibogaine (Journal of Ethnopharmacology).
4. Ayahuasca for Depression:
In a Brazilian study, ayahuasca showed significant antidepressant effects, with a reduction in depression severity scores by 64% one day after treatment (Brazilian Journal of Psychiatry).
RELATED: Find Psilocybin Retreats in Oregon and Around the Globe
5. Psilocybin for End-of-Life Anxiety:
80% of cancer patients showed significant reductions in anxiety and depression after psilocybin therapy (Journal of Psychopharmacology).
6. MDMA for Social Anxiety in Autistic Adults:
A study found a significant decrease in social anxiety symptoms, with a 44.7% reduction in the Liebowitz Social Anxiety Scale score (Psychopharmacology).
7. Ketamine for Chronic Pain:
In a study investigating the effects of ketamine on patients with refractory chronic pain, it was found that ketamine infusions led to a notable reduction in both pain and associated mental health conditions. Specifically, there was a 52% reduction in pain severity, a 33% decrease in pain interference scores, a 28% reduction in depression scores (measured by PHQ-9), and a 36% decrease in anxiety scores (measured by GAD-7) (Future Medicine).
RELATED: Psilocybin Shows Promise in Reducing Stress for First Responders
8. Ibogaine for Substance Dependence:
75% of participants reported reduced craving and withdrawal symptoms after ibogaine treatment for substance dependence (Journal of Psychoactive Drugs)
9. Ayahuasca for Trauma-Related Disorders:
Clinical research indicated a 62% reduction in trauma-related disorder symptoms after ayahuasca therapy (Frontiers in Psychology).
10 . Psilocybin for Smoking Cessation:
80% abstinence rate from smoking was reported six months after psilocybin-assisted therapy (Johns Hopkins Medicine).
Ready to explore a new horizon in mental health? Try out the beta version of HealingChat, HealingMaps AI chatbot that takes all our vetted content, clinics and retreats to answer all your questions in a safe environment. Try the beta version now!
11. Psilocybin for Alcohol Dependence:
A study found that psilocybin-assisted therapy led to a significant reduction in heavy drinking days among participants with alcohol dependence. After receiving psilocybin therapy combined with psychotherapy, participants reported a 59% decrease in heavy drinking days compared to baseline levels (JAMA Psychiatry).
12. Ketamine for Rapid Antidepressant Effects:
71% of patients experienced a significant antidepressant effect within 24 hours of a single ketamine infusion and 35% for at least a week. (Psychiatric Times).
13. Ayahuasca for Personal Growth:
72% of participants reported increased mindfulness and life satisfaction after ayahuasca sessions (Journal of Human Psychopharmacology).
14. Psilocybin for Treatment-Resistant Depression:
42% of participants maintained reduced depression scores 3 months post-treatment (The Lancet Psychiatry).
15. MDMA for PTSD:
Phase 3 clinical trials showed that 67% of participants treated with MDMA-assisted therapy no longer qualified for PTSD after three sessions (MAPS).
RELATED: How I Met Your Mother’s Josh Radnor Met His Wife While On Magic Mushrooms
We’ll be updating this as more data comes out (I’m sure we missed a few already. If you know if any others that should be added here — or any we got wrong — please email [email protected].)
Related reading:
- Psychedelics Show Promise in Reducing Chronic Pain and Opioid Dependence
- Veterans Push for Rescheduling Psychedelics to Increase Research and Access
- Johns Hopkins Recommends Key Safety Measures for Psychedelic Research
See also: — related HealingMaps coverage.
2026 Update
The statistics defining psychedelic medicine’s potential have only grown more striking since 2022. A 2024 study estimated that 5 million Americans meet criteria for treatment-resistant depression alone — making them potential candidates for psilocybin therapy if it receives FDA approval. Meanwhile, Spravato (esketamine) already generates over $400 million quarterly and is on track for $3.5 billion in annual revenue by 2028 — making ketamine therapy the most commercially significant breakthrough mental health treatment of the decade. Over 400 psychedelic clinical trials are now registered on ClinicalTrials.gov, compared to fewer than 50 a decade ago.
June 2026 added a landmark data point: Definium Therapeutics (formerly MindMed) announced positive Phase 3 results for its LSD compound DT120 — the largest psychedelic clinical trial ever completed and the first successful LSD Phase 3 in history. A survey of 11,000 telehealth ketamine patients published in 2024 showed strong safety and sustained remission rates, validating at-home protocols at scale. And 61% of athletes in a 2024 survey reported willingness to try psychedelic-assisted therapy — a cultural shift statistic that reflects how far the field has moved from the fringe. Oregon now has over 300 licensed psilocybin facilitators; industry estimates suggest 50,000-100,000 would be needed nationally after FDA approval.
Frequently Asked Questions
- How many people could benefit from psychedelic therapy?
- A 2024 estimate suggested 5 million Americans have treatment-resistant depression and could be candidates for psilocybin therapy alone. PTSD affects approximately 13 million Americans annually. When including anxiety disorders, addiction, and end-of-life distress, the potential addressable population runs into the tens of millions — a scale that explains why the psychedelic medicine market is projected to reach $10-17 billion within a decade.
- What are the most compelling clinical statistics for psychedelic therapy?
- Several stand out: MDMA produced 67-71% PTSD response rates in Phase 3 trials. A single psilocybin session produced lasting relief from cancer-related anxiety in 80% of patients at 6.5-month follow-up (Johns Hopkins). An 11,000-patient ketamine telehealth study showed sustained remission in the majority of TRD patients. Stanford’s ibogaine study showed dramatic PTSD, depression, and TBI improvement in 18 Special Forces veterans.
- How large is the psychedelic medicine market?
- The U.S. ketamine market generates over $400 million quarterly. Spravato is projected to reach $3.5 billion annually by 2028. The broader psychedelic pharmaceutical market is projected to reach $10-17 billion globally within a decade, depending on FDA approval timelines and reimbursement decisions. The legal psychedelic therapy services market (Oregon, Colorado, New Mexico) is smaller but growing rapidly.
- How has psilocybin use changed in recent years?
- Psilocybin use has increased significantly since Oregon legalized facilitated services in 2022. A 2024 survey found it has become America’s most popular hallucinogen. The combination of legal access in state programs, increased media coverage, and growing clinical legitimacy has driven both recreational and therapeutic use upward. A 2024 study found over a third of Canadian cities have (illegal) magic mushroom dispensaries — indicating demand that formal access has not yet met.
RELATED READING: Ketamine Therapy | Psilocybin Therapy | Psychedelic Therapy
